Medical devices, healthcare technology and the business of care
PMA approval · P240005

enVista Envy hydrophobic acrylic intraocular lens (IOL), enVista Envy toric hydrophobic acrylic intraocular lens (IOL)

Bausch + Lomb, Inc. · Decision date Oct 10, 2024

FDA DECISIONP240005

What did the FDA approve?

FDA records P240005 as an original PMA application. The recorded decision is approval, dated Oct 10, 2024.

FDA approval order statement

Approval for the enVista Envy hydrophobic acrylic intraocular lens (IOL) and the enVista Envy toric hydrophobic acrylic IOL. The enVista Envy hydrophobic acrylic IOL (non-preloaded model: EN / preloaded into shuttle model: EPN) is indicated for primary implantation in the capsular bag of the eye in adult patients for the visual correction of aphakia with less than or equal to 1.0 D preoperative corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL. The enVista Envy Toric hydrophobic acrylic IOL (non-preloaded model: ETN / preloaded into shuttle model: ETPN) is indicated for primary implantation in the capsular bag of the eye in adult patients for the visual correction of aphakia and corneal astigmatism following removal of a cataractous lens to mitigate the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity to an aspheric monofocal IOL.
Regulatory pathway
Original PMA
Clinical specialty
Ophthalmic
Decision date
Oct 10, 2024

FDA source record

Regulatory record facts

Identifier
P240005
Regulatory pathway
Premarket approval application
Product code
MFK
Decision code
APPR
Decision date
Oct 10, 2024
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lens, multifocal intraocular.

Product code
MFK
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240005 received

    Application receipt date recorded by FDA.

  2. P240005 · FDA decision

    APPR

  3. P240005/S007 · Related supplement

    enVista Envy hydrophobic acrylic intraocular lens (IOL)

  4. P240005/S008 · Related supplement

    enVista Envy Hydrophobic Acrylic Intraocular Lens

  5. P240005/S009 · Related supplement

    enVista Envy Hydrophobic Acrylic Intraocular Lens

  6. P240005/S010 · Related supplement

    enVista Envy Hydrophobic Acrylic Intraocular Lens

Timeline entries are records held by MedtechLedger for P240005. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240005

Product / regulatory recordCompanyPathwayDecision dateSource
Bausch + Lomb, Inc.PMA supplementSep 3, 2026FDA
Bausch + Lomb, Inc.PMA supplementSep 30, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 14, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Other records with product code MFK

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bausch + Lomb, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1400 N. Goodman St., Rochester, NY, 14609

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records